文献速递糖尿病垂体与肾上腺疾病

糖尿病继发原因:内分泌学与肿瘤学的交叉路口

Secondary causes of diabetes: a crossroad of endocrinology and oncology.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-01-01

本综述阐述癌症及其治疗(包括靶向治疗、抗体药物偶联物、免疫检查点抑制剂、皮质类固醇和生长抑素受体配体)引起血糖异常的机制,并探讨糖尿病作为癌症早期表现这一常被忽视的方面,最后指出研究空白并倡导协作管理。

要点

  • 癌症及其治疗是糖尿病的关联因素,需关注继发性高血糖。
  • 靶向治疗、免疫治疗等可导致血糖异常,应监测血糖。
  • 糖尿病可能是癌症的早期表现,需警惕继发原因。

核心结论

  • 癌症与糖尿病存在双向关系,癌症及其治疗是糖尿病的关联因素。

研究设计与样本

  • 本综述通过文献总结和案例片段,探讨癌症及治疗相关血糖异常的机制、糖尿病作为癌症早期表现及研究空白。

主要发现

  • 癌症和神经内分泌肿瘤治疗(如PI3K-AKT-mTOR抑制剂、抗体药物偶联物、免疫检查点抑制剂、皮质类固醇和生长抑素受体配体)可导致血糖异常。
  • 糖尿病可能是癌症的早期表现,但常被忽视。

临床怎么用

  • 倡导协作护理方法以管理癌症及其治疗引起的血糖异常。

局限性

  • 指出现有研究空白,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer and diabetes share a bidirectional relationship, with cancer increasingly recognised as an associated factor of diabetes, both from the disease itself and its treatments. In this Review, we aim to: (1) summarise the distinct mechanisms of dysglycaemia arising from cancer and neuroendocrine tumour treatments, including targeted therapies such as PI3K-AKT-mTOR inhibitors, antibody-drug conjugates, immune checkpoint inhibitors, corticosteroids, and somatostatin receptor ligands; (2) examine the often overlooked aspect of the secondary cause of diabetes as an early manifestation of cancer; and (3) highlight research gaps and encourage a collaborative care approach to manage the rising rate of dysglycaemia as a result of cancer and its evolving treatments. To address the first two objectives, we incorporate relevant case vignettes to contextualise the discussions.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Hee NK, Lim QH, Khunti K, et al. Secondary causes of diabetes: a crossroad of endocrinology and oncology. Lancet Diabetes Endocrinol. 2026. PMID: 41991219. doi:10.1016/S2213-8587(26)00027-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。